{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:48:14Z","timestamp":1778521694140,"version":"3.51.4"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T00:00:00Z","timestamp":1525392000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s11912-018-0698-6","type":"journal-article","created":{"date-parts":[[2018,5,4]],"date-time":"2018-05-04T00:45:10Z","timestamp":1525394710000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Systemic Therapies for Advanced Squamous Cell Anal Cancer"],"prefix":"10.1007","volume":"20","author":[{"given":"Francesco","family":"Sclafani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheela","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,4]]},"reference":[{"key":"698_CR1","unstructured":"National Cancer Institute. Surveillance, epidemiology, and end results program. Available at: \n                      https:\/\/seer.cancer.gov\/statfacts\/html\/anus.html\n                      \n                     (accessed on 09.12.2017)."},{"key":"698_CR2","first-page":"401","volume":"71","author":"RP Zee Van der","year":"2013","unstructured":"Van der Zee RP, Richel O, de Vries HJC, Prins JM. The increasing incidence of anal cancer: can it be explained by trends in risk groups? Neth J Med. 2013;71:401\u201311.","journal-title":"Neth J Med"},{"key":"698_CR3","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.30716","volume":"141","author":"C Martel de","year":"2017","unstructured":"de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141:664\u201370.","journal-title":"Int J Cancer"},{"key":"698_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/cncr.20365","volume":"101","author":"JR Daling","year":"2004","unstructured":"Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101:270\u201380.","journal-title":"Cancer"},{"key":"698_CR5","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJM199711063371904","volume":"337","author":"M Frisch","year":"1997","unstructured":"Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997;337:1350\u20138.","journal-title":"N Engl J Med"},{"issue":"5","key":"698_CR6","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1097\/00126334-200412150-00004","volume":"37","author":"M Bower","year":"2004","unstructured":"Bower M, Powles T, Newsom-Davis T, Thirlwell C, Stebbing J, Mandalia S, et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr. 2004;37(5):1563\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"698_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S1470-2045(07)70043-8","volume":"8","author":"G Edgren","year":"2007","unstructured":"Edgren G, Sparen P. Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol. 2007;8:311\u20136.","journal-title":"Lancet Oncol"},{"key":"698_CR8","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/his.12574","volume":"66","author":"JF Fl\u00e9jou","year":"2015","unstructured":"Fl\u00e9jou JF. An update on anal neoplasia. Histopathology. 2015;66:147\u201360.","journal-title":"Histopathology"},{"key":"698_CR9","unstructured":"Welton MR, Lambert R, Bosman FT. Tumour of the anal canal. In Bosman FT, Carneiro F, Hruban RH, Theise ND eds. WHO classification of tumours of the digestive system. 4th edition Lyon, IARC 2010;183\u2013193."},{"key":"698_CR10","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","volume":"348","author":"JMA Northover","year":"1996","unstructured":"Northover JMA, Arnott SJ, Cunningham D, et al. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet. 1996;348:1049\u201354.","journal-title":"Lancet"},{"key":"698_CR11","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","volume":"14","author":"M Flam","year":"1996","unstructured":"Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527\u201339.","journal-title":"J Clin Oncol"},{"key":"698_CR12","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"H Bartelink","year":"1997","unstructured":"Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15:2040\u20139.","journal-title":"J Clin Oncol"},{"key":"698_CR13","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","volume":"102","author":"J Northover","year":"2010","unstructured":"Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010;102:1123\u20138.","journal-title":"Br J Cancer"},{"key":"698_CR14","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","volume":"14","author":"RD James","year":"2013","unstructured":"James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 \u00d7 2 factorial trial. Lancet Oncol. 2013;14:516\u201324.","journal-title":"Lancet Oncol."},{"key":"698_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12029-015-9790-4","volume":"47","author":"SC Oliveira","year":"2016","unstructured":"Oliveira SC, Moniz CM, Riechelmann R, et al. Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal. J Gastrointest Cancer. 2016;47:75\u201381.","journal-title":"J Gastrointest Cancer."},{"key":"698_CR16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/bjs.4908","volume":"92","author":"AG Renehan","year":"2005","unstructured":"Renehan AG, Saunders MP, Schofield PF, O\u2019Dwyer ST. Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg. 2005;92:605\u201314.","journal-title":"Br J Surg"},{"key":"698_CR17","first-page":"281","volume":"40","author":"TD Lindell","year":"1974","unstructured":"Lindell TD, Moseley S, Fletcher WS, Combination CCNU. Bleomycin therapy for squamous cell carcinoma. Am Surg. 1974;40:281\u20139.","journal-title":"Am Surg"},{"key":"698_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/1097-0142(197601)37:1<12::AID-CNCR2820370103>3.0.CO;2-X","volume":"37","author":"HK Newman","year":"1976","unstructured":"Newman HK, Quan SH. Multi-modality therapy for epidermoid carcinoma of the anus. Cancer. 1976;37:12\u20139.","journal-title":"Cancer"},{"key":"698_CR19","first-page":"91","volume":"62","author":"WB Fisher","year":"1978","unstructured":"Fisher WB, Herbst KD, Sims JE, Critchfield CF. Metastatic cloacogenic carcinoma of the anus: sequential responses to adriamycin and cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 1978;62:91\u20137.","journal-title":"Cancer Treat Rep"},{"key":"698_CR20","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1002\/1097-0142(19811215)48:12<2569::AID-CNCR2820481206>3.0.CO;2-X","volume":"48","author":"S Zimm","year":"1981","unstructured":"Zimm S, Wampler GL. Response of metastatic cloacogenic carcinoma to treatment with semustine. Cancer. 1981;48:2575\u20136.","journal-title":"Cancer"},{"key":"698_CR21","first-page":"257","volume":"6","author":"RW Carey","year":"1984","unstructured":"Carey RW. Regression of pulmonary metastases from cloacogenic carcinoma after cis-platinum\/5-fluorouracil treatment. J Clin Gastroenterol. 1984;6:257\u20139.","journal-title":"J Clin Gastroenterol"},{"key":"698_CR22","first-page":"1345","volume":"70","author":"R Khater","year":"1986","unstructured":"Khater R, Frenay M, Bourry J, Milano G, Namer M. Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases. Cancer Treat Rep. 1986;70:1345\u20136.","journal-title":"Cancer Treat Rep."},{"key":"698_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0002-9343(89)80702-8","volume":"87","author":"JA Ajani","year":"1989","unstructured":"Ajani JA, Carrasco CH, Jackson DE, Wallace S. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med. 1989;87:221\u20134.","journal-title":"Am J Med"},{"key":"698_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0936-6555(05)80699-5","volume":"5","author":"TR Evans","year":"1993","unstructured":"Evans TR, Mansi JL, Glees JP. Response of metastatic anal carcinoma to single agent carboplatin. Clin Oncol (R Coll Radiol). 1993;5:57\u20138.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"698_CR25","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/00000421-199312000-00017","volume":"16","author":"IA Jaiyesimi","year":"1993","unstructured":"Jaiyesimi IA, Pazdur R. Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. Am J Clin Oncol. 1993;16:536\u201340.","journal-title":"Am J Clin Oncol"},{"key":"698_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3109\/02841869309083882","volume":"32","author":"G Tanum","year":"1993","unstructured":"Tanum G. Treatment of relapsing anal carcinoma. Acta Oncol. 1993;32:33\u20135.","journal-title":"Acta Oncol"},{"key":"698_CR27","first-page":"861","volume":"86","author":"C Faivre","year":"1999","unstructured":"Faivre C, Rougier P, Ducreux M, Mitry E, Lusinchi A, Lasser P, et al. 5-Fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer. Bull Cancer. 1999;86:861\u20135.","journal-title":"Bull Cancer"},{"key":"698_CR28","doi-asserted-by":"publisher","first-page":"11133","DOI":"10.18632\/oncotarget.2563","volume":"5","author":"C Eng","year":"2014","unstructured":"\u2022 Eng C, Chang GJ, You YN, et al. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget. 2014;5:11133\u201342. Largest retrospective series of advanced anal cancer patients treated with systemic chemotherapy.","journal-title":"Oncotarget"},{"key":"698_CR29","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1634\/theoncologist.2016-0241","volume":"22","author":"F Sclafani","year":"2017","unstructured":"\u2022 Sclafani F, Morano F, Cunningham D, et al. Platinum-fluoropyrimidine and paclitaxel-based chemotherapy in the treatment of advanced anal cancer patients. Oncologist. 2017;22:402\u20138. Second largest retrospective series of advanced anal cancer patients treated with systemic chemotherapy.","journal-title":"Oncologist"},{"key":"698_CR30","doi-asserted-by":"publisher","unstructured":"Kohen AA, Wang K, Boland PM. Systemic therapy for advanced anorectal squamous cell carcinomas: a single institutional experience. J Clin Oncol. 2016;34 Suppl 4: 728. \n                      https:\/\/doi.org\/10.1200\/jco.2016.34.4_suppl.728","DOI":"10.1200\/jco.2016.34.4_suppl.728"},{"key":"698_CR31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000361051","volume":"87","author":"R Kim","year":"2014","unstructured":"Kim R, Byer J, Fulp WJ, Mahipal A, Dinwoodie W, Shibata D. Carboplatin and paclitaxel treatment is effective in advanced anal cancer. Oncology. 2014;87:125\u201332.","journal-title":"Oncology"},{"key":"698_CR32","first-page":"4637","volume":"31","author":"A Abbas","year":"2011","unstructured":"Abbas A, Nehme E, Fakih M. Single-agent paclitaxel in advanced anal cancer after failure of cisplatin and 5-fluorouracil chemotherapy. Anticancer Res. 2011;31:4637\u201340.","journal-title":"Anticancer Res"},{"key":"698_CR33","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/1097-0142(19860401)57:7<1437::AID-CNCR2820570733>3.0.CO;2-T","volume":"57","author":"MJ Greenall","year":"1986","unstructured":"Greenall MJ, Magill GB, Quan SH, DeCosse JJ. Recurrent epidermoid cancer of the anus. Cancer. 1986;57:1437\u201341.","journal-title":"Cancer"},{"key":"698_CR34","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/BF00263905","volume":"15","author":"N Wilking","year":"1985","unstructured":"Wilking N, Petrelli N, Herrera L, Mittelman A. Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal. Cancer Chemother Pharmacol. 1985;15:300\u20132.","journal-title":"Cancer Chemother Pharmacol"},{"key":"698_CR35","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10637-006-7667-x","volume":"24","author":"M Jhawer","year":"2006","unstructured":"Jhawer M, Mani S, Lefkopoulou M, Hahn RG, Harris J, Catalano PJ, et al. Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: an eastern cooperative oncology group study E7282. Investig New Drugs. 2006;24:447\u201354.","journal-title":"Investig New Drugs"},{"key":"698_CR36","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/1097-0142(20010801)92:3<642::AID-CNCR1365>3.0.CO;2-Z","volume":"92","author":"JD Hainsworth","year":"2001","unstructured":"Hainsworth JD, Burris HA III, Meluch AA, Baker MN, Morrissey LH, Greco FA. Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a phase II trial. Cancer. 2001;92:642\u20139.","journal-title":"Cancer"},{"key":"698_CR37","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1093\/annonc\/mdt396","volume":"24","author":"S Kim","year":"2013","unstructured":"Kim S, Jary M, Mansi L, Benzidane B, Cazorla A, Demarchi M, et al. DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. Ann Oncol. 2013;24:3045\u201350.","journal-title":"Ann Oncol"},{"key":"698_CR38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000259615","volume":"77","author":"N Lukan","year":"2009","unstructured":"Lukan N, Str\u00f6bel P, Willer A, Kripp M, Dinter D, Mai S, et al. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology. 2009;77:293\u20139.","journal-title":"Oncology"},{"issue":"8","key":"698_CR39","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/CAD.0000000000000383","volume":"27","author":"JE Rogers","year":"2016","unstructured":"Rogers JE, Ohinata A, Silva NN, Mehdizadeh A, Eng C. Epidermal growth factor receptor inhibition in metastatic anal cancer. Anti-Cancer Drugs. 2016;27(8):804\u20138.","journal-title":"Anti-Cancer Drugs"},{"key":"698_CR40","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000452766","volume":"92","author":"DW Kim","year":"2017","unstructured":"Kim DW, Byer J, Kothari N, Mahipal A, Chang YD, Kim RD. EGFR inhibitors in patients with advanced squamous cell anal carcinomas: a single-institution experience. Oncology. 2017;92:190\u20136.","journal-title":"Oncology"},{"key":"698_CR41","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","volume":"28","author":"PA Ott","year":"2017","unstructured":"\u2022\u2022 Ott PA, Piha-Paul SA, Munster P, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol. 2017;28:1036\u201341. Phase Ib study showing activity of the immune checkpoint inhibitor pembrolizumab in advanced anal cancer.","journal-title":"Ann Oncol"},{"key":"698_CR42","unstructured":"\u2022\u2022 Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:446\u201353. Phase II study showing activity of the immune checkpoint inhibitor nivolumab in pre-treated, advanced anal cancer."},{"key":"698_CR43","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Bendell JC, Eng C, Moore KN, et al. Checkpoint kinase (CHK) 1\/2 inhibitor LY2606368 in a phase I, dose-expansion study in patients (pts) with metastatic squamous cell carcinoma (mSCC) of the anus. J Clin Oncol. 2015;33 suppl 15: 3520 \n                      https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.3520\n                      \n                     Phase Ib study showing activity of the cell cycle checkpoint inhibitor LY2606368 in pre-treated, advanced anal cancer.","DOI":"10.1200\/jco.2015.33.15_suppl.3520"},{"key":"698_CR44","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.ejso.2014.07.030","volume":"40","author":"R Glynne-Jones","year":"2014","unstructured":"Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2014;40:1165\u201376.","journal-title":"Eur J Surg Oncol"},{"key":"698_CR45","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Anal carcinoma. Version 2.2017. Available at: \n                      http:\/\/www.nccn.org\/professionals\/\n                      \n                     physician_gls\/pdf\/anal.pdf. Accessed on January 12, 2016."},{"key":"698_CR46","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1002\/1097-0142(20011115)92:10<2592::AID-CNCR1612>3.0.CO;2-4","volume":"92","author":"B Damascelli","year":"2001","unstructured":"Damascelli B, Cant\u00fa G, Mattavelli F, et al. Intra-arterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical act. Cancer. 2001;92:2592\u2013602.","journal-title":"Cancer"},{"key":"698_CR47","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00384-008-0467-3","volume":"23","author":"T Alcindor","year":"2008","unstructured":"Alcindor T. Activity of paclitaxel in metastatic squamous anal carcinoma. Int J Color Dis. 2008;23:717.","journal-title":"Int J Color Dis"},{"key":"698_CR48","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1186\/s12885-017-3566-0","volume":"17","author":"S Kim","year":"2017","unstructured":"Kim S, Jary M, Andr\u00e9 T, Vendrely V, Buecher B, Fran\u00e7ois E, et al. Docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). BMC Cancer. 2017;17:574.","journal-title":"BMC Cancer"},{"key":"698_CR49","first-page":"163736","volume":"2011","author":"DV Golub","year":"2011","unstructured":"Golub DV, Civelek AC, Sharma VR. A regimen of taxol, ifosfamide, and platinum for recurrent advanced squamous cell cancer of the anal canal. Chemother Res Pract. 2011;2011:163736.","journal-title":"Chemother Res Pract"},{"key":"698_CR50","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1309\/X4UADHVN317V2XMW","volume":"124","author":"LH L\u00ea","year":"2005","unstructured":"L\u00ea LH, Chetty R, Moore MJ. Epidermal growth factor receptor expression in anal canal carcinoma. Am J Clin Pathol. 2005;124:20\u20133.","journal-title":"Am J Clin Pathol"},{"key":"698_CR51","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/1471-2407-10-189","volume":"10","author":"N Damme Van","year":"2010","unstructured":"Van Damme N, Deron P, Van Roy N, et al. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer. 2010;10:189.","journal-title":"BMC Cancer"},{"key":"698_CR52","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1038\/bjc.2012.479","volume":"107","author":"A Paliga","year":"2012","unstructured":"Paliga A, Onerheim R, Gologan A, Chong G, Spatz A, Niazi T, et al. EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? Br J Cancer. 2012;107:1864\u20138.","journal-title":"Br J Cancer"},{"key":"698_CR53","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1093\/annonc\/mdt368","volume":"24","author":"E Deutsch","year":"2013","unstructured":"Deutsch E, Lemanski C, Pignon JP, Levy A, Delarochefordiere A, Martel-Lafay I, et al. Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Ann Oncol. 2013;24:2834\u20138.","journal-title":"Ann Oncol"},{"key":"698_CR54","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1200\/JCO.2016.69.1667","volume":"35","author":"MK Garg","year":"2017","unstructured":"Garg MK, Zhao F, Sparano JA, Palefsky J, Whittington R, Mitchell EP, et al. Cetuximab plus chemoradiotherapy in immunocompetent patients with anal carcinoma: a phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol. 2017;35:718\u201326.","journal-title":"J Clin Oncol"},{"key":"698_CR55","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1200\/JCO.2016.69.1642","volume":"35","author":"JA Sparano","year":"2017","unstructured":"Sparano JA, Lee JY, Palefsky J, Henry DH, Wachsman W, Rajdev L, et al. Cetuximab plus chemoradiotherapy for HIV-associated anal carcinoma: a phase II AIDS malignancy consortium trial. J Clin Oncol. 2017;35:727\u201333.","journal-title":"J Clin Oncol"},{"key":"698_CR56","doi-asserted-by":"crossref","unstructured":"Phan LK, Hoff PM. Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Dis Colon rectum. 2007;50:395\u20138.","DOI":"10.1007\/s10350-006-0786-9"},{"key":"698_CR57","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/030089161009600419","volume":"96","author":"S Dosso De","year":"2010","unstructured":"De Dosso S, Martin V, Zanellato E, Frattini M, Saletti P. Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma. Tumori. 2010;96:627\u20138.","journal-title":"Tumori"},{"key":"698_CR58","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1159\/000341371","volume":"5","author":"H Barmettler","year":"2012","unstructured":"Barmettler H, Komminoth P, Schmid M, Duerr D. Efficacy of cetuximab in combination with FOLFIRI in a patient with KRAS wild-type metastatic anal cancer. Case Rep Oncol. 2012;5:428\u201333.","journal-title":"Case Rep Oncol"},{"key":"698_CR59","doi-asserted-by":"publisher","first-page":"125467","DOI":"10.1155\/2011\/125467","volume":"2011","author":"MW Saif","year":"2011","unstructured":"Saif MW, Kontny E, Syrigos KN, Shahrokni A. The role of EGFR inhibitors in the treatment of metastatic anal canal carcinoma: a case series. J Oncol. 2011;2011:125467.","journal-title":"J Oncol"},{"issue":"Suppl 1","key":"698_CR60","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s12029-014-9626-7","volume":"45","author":"JE Rogers","year":"2014","unstructured":"Rogers JE, Eng C. Cetuximab in refractory squamous cell carcinoma of the anal canal. J Gastrointest Cancer. 2014;45(Suppl 1):198\u2013200.","journal-title":"J Gastrointest Cancer"},{"key":"698_CR61","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1177\/1078155214526268","volume":"21","author":"M Khawandanah","year":"2015","unstructured":"Khawandanah M, Baxley A, Pant S. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin\/cetuximab. J Oncol Pharm Pract. 2015;21:232\u20137.","journal-title":"J Oncol Pharm Pract"},{"key":"698_CR62","first-page":"E82","volume":"6","author":"JE Rogers","year":"2015","unstructured":"Rogers JE, Silva NN, Eng C. Cetuximab in combination with cisplatin and 5-fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal. J Gastrointest Oncol. 2015;6:E82\u20135.","journal-title":"J Gastrointest Oncol"},{"key":"698_CR63","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1126\/science.2157286","volume":"248","author":"BA Werness","year":"1990","unstructured":"Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990;248:76\u20139.","journal-title":"Science"},{"key":"698_CR64","first-page":"4620","volume":"56","author":"SN Boyer","year":"1996","unstructured":"Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 1996;56:4620\u20134.","journal-title":"Cancer Res"},{"key":"698_CR65","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1158\/0008-5472.CAN-12-2384","volume":"73","author":"S Lyford-Pike","year":"2013","unstructured":"Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 2013;73:1733\u201341.","journal-title":"Cancer Res"},{"issue":"9","key":"698_CR66","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","volume":"5","author":"A Ribas","year":"2015","unstructured":"Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015;5(9):915\u20139.","journal-title":"Cancer Discov"},{"key":"698_CR67","doi-asserted-by":"publisher","unstructured":"Hinrichs CS, Doran SL, Stevanovic S, et al. A phase I\/II clinical trial of E6 T-cell receptor gene therapy for human papillomavirus (HPV)-associated epithelial cancers. J Clin Oncol. 2017;35 suppl 15: 3009 \n                      https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.3009\n                      \n                    .","DOI":"10.1200\/JCO.2017.35.15_suppl.3009"},{"key":"698_CR68","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1200\/JCO.2017.74.9291","volume":"36","author":"V Col\u00f3n-L\u00f3pez","year":"2018","unstructured":"Col\u00f3n-L\u00f3pez V, Shiels MS, Machin M, Ortiz AP, Strickler H, Castle PE, et al. Anal cancer risk among people with HIV infection in the United States. J Clin Oncol. 2018;36:68\u201375.","journal-title":"J Clin Oncol"},{"key":"698_CR69","doi-asserted-by":"crossref","unstructured":"Bower M, Palfreeman A, Alfa-Wali M, et al. British HIV Association guidelines for HIV-associated malignancies 2014. HIV Med. 2014:15(Suppl. 2):1\u201392.","DOI":"10.1111\/hiv.12136"},{"key":"698_CR70","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Sclafani F, Adams R, Eng C, et al. InterAACT: An international multicenter open label randomized phase II advanced anal cancer trial comparing cisplatin (CDDP) plus 5-fluorouracil (5-FU) versus carboplatin (CBDCA) plus weekly paclitaxel (PTX) in patients with inoperable locally recurrent (ILR) or metastatic disease. J Clin Oncol. 2015;33 suppl 3: published online before print. \n                      https:\/\/doi.org\/10.1200\/jco.2015.33.3_suppl.tps792\n                      \n                     First, ever-conducted, prospective, randomised clinical trial in the setting of advanced anal cancer.","DOI":"10.1200\/jco.2015.33.3_suppl.tps792"},{"key":"698_CR71","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jamaoncol.2017.0115","volume":"3","author":"EL Yanik","year":"2017","unstructured":"Yanik EL, Kaunitz GJ, Cottrell TR, Succaria F, McMiller TL, Ascierto ML, et al. Association of HIV status with local immune response to anal squamous cell carcinoma: implications for immunotherapy. JAMA Oncol. 2017;3:974\u20138.","journal-title":"JAMA Oncol"},{"key":"698_CR72","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1038\/sj.bjc.6605984","volume":"103","author":"T Lampejo","year":"2010","unstructured":"Lampejo T, Kavanagh D, Clark J, Goldin R, Osborn M, Ziprin P, et al. Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review. Br J Cancer. 2010;103:1858\u201369.","journal-title":"Br J Cancer"},{"key":"698_CR73","doi-asserted-by":"publisher","first-page":"43594","DOI":"10.18632\/oncotarget.6202","volume":"6","author":"BG Smaglo","year":"2015","unstructured":"\u2022 Smaglo BG, Tesfaye A, Halfdanarson TR, et al. Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. Oncotarget. 2015;6:43594\u2013604. Largest study investigating the molecular biology of anal cancer using a multiplatform analytic approach.","journal-title":"Oncotarget"},{"key":"698_CR74","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1093\/annonc\/mdw152","volume":"27","author":"JH Chung","year":"2016","unstructured":"Chung JH, Sanford E, Johnson A, Klempner SJ, Schrock AB, Palma NA, et al. Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. Ann Oncol. 2016;27:1336\u201341.","journal-title":"Ann Oncol"},{"key":"698_CR75","doi-asserted-by":"crossref","unstructured":"Weinberg BA, Lenz H-J, Arguello D, El-Deiry WS, Xiu J, Gatalica Z, et al. Molecular characterization of squamous cell carcinoma of the anal canal (SCCA). J Clin Oncol. 2017;35(suppl 4S; abstract 538)","DOI":"10.1200\/JCO.2017.35.4_suppl.538"},{"key":"698_CR76","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1158\/1541-7786.MCR-17-0060","volume":"15","author":"V Morris","year":"2017","unstructured":"Morris V, Rao X, Pickering C, Foo WC, Rashid A, Eterovic K, et al. Comprehensive genomic profiling of metastatic squamous cell carcinoma of the anal canal. Mol Cancer Res. 2017;15:1542\u201350.","journal-title":"Mol Cancer Res"},{"key":"698_CR77","doi-asserted-by":"crossref","unstructured":"Evesque L, Benezery K, Follana P, Tuan Falk A, Doyen J, Reure J, et al. Multimodal therapy of metastatic squamous cell carcinoma of the anus: a single institution experience. Dis Colon rectum. 2017;60:785\u201391.","DOI":"10.1097\/DCR.0000000000000827"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-018-0698-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-018-0698-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-018-0698-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T19:23:45Z","timestamp":1556911425000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-018-0698-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,4]]},"references-count":77,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["698"],"URL":"https:\/\/doi.org\/10.1007\/s11912-018-0698-6","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,4]]},"assertion":[{"value":"4 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Francesco Sclafani declares that he has no conflict of interest.Sheela Rao has received compensation from Bristol-Myers Squibb for service as a consultant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"53"}}